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Cell apoptosisa b s t r a c t
Maintaining the functional integrity of mitochondria is crucial for cell function, signal transduction
and overall cell activities. Mitochondrial dysfunctions may alter energy metabolism and in many
cases are associated with neurological diseases. Recent studies have reported that mutations in
dehydrogenase E1 and transketolase domain-containing 1 (DHTKD1), a mitochondrial protein
encoding gene, could cause neurological abnormalities. However, the function of DHTKD1 in mito-
chondria remains unknown. Here, we report a strong correlation of DHTKD1 expression level with
ATP production, revealing the fact that DHTKD1 plays a critical role in energy production in mito-
chondria. Moreover, suppression of DHTKD1 leads to impaired mitochondrial biogenesis and
increased reactive oxygen species (ROS), thus leading to retarded cell growth and increased cell
apoptosis. These ﬁndings demonstrate that DHTKD1 contributes to mitochondrial biogenesis and
function maintenance.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mitochondria are constituted of about 1500 proteins. The
majority are encoded by nuclear genome, while only about 1%
are encoded by mitochondrial DNA (mtDNA) independently [1].
Thus, maintain the integrity and interaction between mitochon-
drial and nuclear genomes is necessity for well-functioning mito-
chondria [2]. Mitochondria were long viewed as vital but static
energy factories, furthermore, mitochondria have been found to
maintain overall mitochondrial morphology and function in accor-
dance with the cell cycle, cell differentiation, metabolic rates and
energy requirement [3]. The precise control of the mitochondrial
amount through regulation of biogenesis and degradation is one
of the key elements involved in appropriate mitochondrial and cell
function [2]. Mitochondrial dysfunction caused by various abnor-
malities can lead to apoptosis, mtDNA mutations, and a severe
reduction in energy production. Mitochondrial abundance, integ-
rity, activity, and normal morphology is crucial for a cell, thus dam-
age of mitochondria can cause many cell dysfunctions, even
impairing cell survival leading to death [1]. Indeed, dysfunctionof mitochondria is linked to the development of various human
diseases, including neurodegenerative conditions, metabolic syn-
dromes and cancers [4–6].
Dehydrogenase E1 and transketolase domain containing protein
1 (DHTKD1) gene is localized in chromosomal region 10p14 [7].
DHTKD1 was ﬁrst cloned by Nagase’s group in 2000 [8], and it is
consisted of 17 exons with an open reading frame (ORF) of 5202
base pairs length, encoding a proposed mitochondrial protein with
919 amino acids [9,10]. The product of this gene was similar to
oxoglutarate dehydrogenase (OGDH) and OGDH like protein
(OGDHL) [7], and was presumed to function as an E1 component
of dehydrogenase complex in tricarboxylic acid (TCA) cycle or else-
where, and might play an critical role in energy production in
mitochondria. Recently, we reported a heterozygous nonsense
mutation in DHTKD1 was the cause of Charcot–Marie–Tooth dis-
ease type 2Q (CMT2Q), one of the most common inherited neuro-
degenerative diseases. We demonstrated that DHTKD1 mRNA
transcripts containing premature stop codons were degraded
through the nonsense-mediated mRNA decay (NMD) and thus
led to a signiﬁcantly lower protein level [10]. At the same time,
Prokisch’s group reported their ﬁndings about DHTKD1 mutations
in human 2-aminoadipic and 2-oxoadipic aciduria, which was an
L-lysine metabolism disorder, featuring with mild to severe neuro-
logical symptoms, caused by impaired turnover of decarboxylation
2-oxoadipate to glutaryl-CoA [11]. These studies implied a critical
Table 1
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development.
In humans, mitochondrial dysfunction is associated with
various neurological disorders [12]. Here, mutations in the mito-
chondrial protein DHTKD1, leading to a number of neuropathies,
deserve special attention. However, it remains unknown how
DHTKD1 mediates TCA cycle. There also remain concerns about
why mutations in DHTKD1 would have a negative impact on
neurological function. To explore the function of DHTKD1 on
mitochondria, we silenced DHTKD1 with siRNAs. It was found that
suppression of DHTKD1 could decrease ATP production. Moreover,
reduction of DHTKD1 led to impaired mitochondrial biogenesis, as
well as increased cellular ROS level. These ﬁndings demonstrate
that DHTKD1 may participate in energy metabolic regulation,
mitochondrial biogenesis and early apoptosis induction. The
mechanism of DHTKD1 related to human metabolic dysfunction,








50-ATGGAATGCTTGAAGGCTGC-302. Materials and methods
2.1. Cell culture
Hepatic carcinoma cell HepG2, glioma cell line U87MG and
gastric carcinoma cell NCI-N87 were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) or RPMI 1640-based complete medium
respectively, supplemented with 10% heat-inactivated fetal calf
serum, 100 units/ml penicillin, and 100 lg/ml streptomycin at
37 C in a 5% humidiﬁed CO2 atmosphere.
2.2. Immunoblotting
Total cell lysates were prepared in lysis buffer. Proteins were
separated by SDS–PAGE, transferred to nitrocellulose membranes
and probed with anti-DHTKD1 (Abnova).
2.3. RNA isolation and quantitative real-time PCR
Total RNA was isolated with TRIzol reagent (Takara) according
to the manufacturer’s instructions, and then was reverse
transcribed with AMV reverse transcriptase (Takara). Quantitative
PCR was carried out with SYBR Green PCR kit (Takara) according to
the manufacturer’s instructions. Ampliﬁcations were performed
in Mastercycler ep realplex (Eppendorf). Relative transcript
quantities were calculated using the DDCt method with b-ACTIN
as the endogenous reference gene. Each sample was analyzed in
triplicate. Primer sequences were listed in Table 1.
2.4. Gene silencing by siRNA transfection
siRNA oligonucleotides targeting human DHTKD1 and control
oligonucleotides were from RIBOBIO. Transfections were carried
out using siRNA transfection reagent (Roche) according to the
manufacturer’s instructions. Cells were seeded in six-well plates
and transfected after 24 h with 100 nM DHTKD1 or negative
control siRNA. After 48–72 h, cells were harvested for subsequent
assays.
2.5. OGDHC assays
OGDHC preparation and activity analysis procedures has been
described previously [13]. Transfected HepG2 cells were ﬁrst
resuspended with buffer 1, and then lysed with one third volumes
of buffer 2 at least 20 min on ice before the assay. 3–5 ll cell
lysates were added to the total 1 ml of the OGDHC assay medium.
Reaction rates of OGDHC were determined by the accumulation ofthe reaction product NADH at 340 nm. The product accumulation
curves were followed for 30–120 s. The values were normalized
to total protein amount.
2.6. ATP quantitation
ATP contents were determined using the luciferin/luciferase-
based ATP Bioluminescence Assay Kit (Beyotime) according to
the manufacturer’s instructions. Transfected cells were lysed in
lysis buffer and 10 ll supernatant was added to 100 ll reaction
buffer for the immediately detection. All samples were measured
in triplicates and the values were normalized as nmol/mg protein.
2.7. ROS assays
ROS level was measured by a ﬂuorescent method with ﬂow
cytometry. DCFH-DA (Beyotime) was used as indicator of cellular
ROS. Transfected cells were incubated with DCFH-DA at 37 C for
20 min. The intensity of ﬂuorescence was analyzed to quantify
the ROS level.
2.8. Real-time PCR of mtDNA
Mitochondrial DNA (mtDNA) copy number was quantiﬁed by
qPCR from isolated total DNA using previously described method
[14]. All samples were measured in triplicates and qPCR results
obtained were conﬁrmed by three independent experiments. We
ﬁrst normalized the amount of mtDNA to the amount of the nDNA
and then calculated the percentage of mtDNA present in DHTKD1-
siRNA-transfected cells as a ratio relative to mtDNA of ctrl-siRNA-
transfected cells. The primers used were listed in Table 1.
2.9. MTT assays
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was used to measure cell proliferation.
Logarithmically negative control and DHTKD1-siRNA-transfected
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and incubated in a humidiﬁed atmosphere (37 C and 5% CO2).
After culturing cells for an appropriate time, 10 ll of 5 mg/ml
MTT (Sigma) was added into each well and continued to culture
for 4 h. Then, the cell culture medium was replaced by 100 ll of di-
methyl sulfoxide (Sigma). Thirty minutes after dimethyl sulfoxide
addition, optical density was read at 490 nm wavelength and cell
growth curves were determined according to the optical density
values.
2.10. Cell apoptosis and cell cycle analysis
Cells transfected with siRNA were harvested and stained with
Annexin V-FITC apoptosis detection kit (KeyGEN) and then
analyzed by ﬂow cytometry. In brief, transfected cells were
collected, washed, and resuspended in 500 ll binding buffer and
then incubated with 5 ll FITC-conjugated annexin-V and PI (propi-
dium iodide) in the dark for 15 min at room temperature. For cell
cycle analysis, harvested cell were stained with PI after ﬁxed with
ethanol. All samples were analyzed by ﬂow cytometry, and data
were processed with the FlowJo software.
2.11. Statistical analysis
All quantitative data in this study were presented as
mean ± S.D. A two-tailed Student’s t-test was used to analyze com-
parisons between two groups. P < 0.05 was considered statistically
signiﬁcant.Fig. 1. DHTKD1 is involved in normal mitochondrial functions. (A) Knock-down and ove
DHTKD1 vector, respectively. DHTKD1 protein was detected with His or DHTKD1 a
overexpressed (right) HepG2 cells. (C) ATP content was measured in the same cells as sh
U87MG cells. All quantitative data is presented in means ± S.D. of three independent ex3. Results
3.1. DHTKD1 is involved in mitochondrial functions
DHTKD1 was presumed to be similar to OGDH [7]. Previously,
DHTKD1 was proved to localize to mitochondria [10], raising the
possibility that DHTKD1 plays a role in mitochondria through the
TCA cycle. Mitochondrial energy production critically depends on
the proper functioning of multiple enzyme complexes, such as
multienzyme OGDHC, which catalyzes a highly regulated step of
the mitochondrial TCA cycle, being essential for the organism’s
development and survival [15]. To disrupt this balance by modu-
lating the expression level of DHTKD1 is expected to affect the
mitochondrial function. In the present work, we sought experi-
mental evidence to support this hypothesis. We silenced DHTKD1
using siRNA oligomers [10] in hepatic carcinoma cell HepG2, gli-
oma cell U87MG and gastric carcinoma cell NCI-N87. The result
showed that DHTKD1 was effectively silenced (Fig. 1A and Supple-
mentary Fig. 1A). Along with DHTKD1 suppression, initial OGDHC
activity was reduced by 14% as compared to controls
(P = 0.0314), whereas it was not affected by DHTKD1 overexpres-
sion (Fig. 1B). The observed response to the DHTKD1 inhibition,
ATP level displayed a modest decrease as compared to the control
cells (P = 0.0318) (Fig. 1C), which was associated with the repres-
sion of oxidative phosphorylation (OXPHOS) genes (ATP synthase,
cytochrome C and cytochrome C oxidase) (Fig. 1D and Supplemen-
tary Fig. 1C). It is important to note here that up-regulation of
DHTKD1 increased ATP level markedly (Fig. 1C), suggesting anrexpression of DHTKD1 in HepG2 cells via transfected with DHTKD1 siRNA and His-
ntibody. (B) OGDHC activity was measured in DHTKD1 knock-down (left) and
own in (B). (D) OXPHOS genes expression was detected by RT-qPCR in HepG2 and
periments. NS, non-signiﬁcant, ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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function and mitochondrial energy metabolism. Taken together,
these results further reveal the fact that suppression of DHTKD1
displays impairment of mitochondrial function.
3.2. DHTKD1 inhibition impairs mitochondrial biogenesis
Given the functional evidence for mitochondrial dysfunction,
we ﬁrst evaluated mitochondrial amount in cultured cells. We
stained cells with mitochondrial speciﬁc probe, MitoTracker Red.
We found that ﬂuorescence produced by DHTKD1 siRNA-transfec-
ted cells was weaker than that of controls (Fig. 2A). Then, we fur-
ther assessed mtDNA copy number via real-time qPCR described
by Hayashi [14]. The amounts of mt-COX1 (cytochrome C oxidase
subunit 1) and mt-CYTB (cytochrome b) DNA relative to the levels
of H19, a nuclear DNA (nDNA)-encoded gene, were markedly re-
duced in DHTKD1 silenced cells compared to controls (Fig. 2B and
Supplementary Fig. 1B). These results demonstrated DHTKD1 deﬁ-
ciency led to reduced mitochondrion. Furthermore, we detected
the expression of several genes involved in mitochondrial biogen-
esis. Consistently, PGC-1b, NRF1 and TFAM expression was lower in
DHTKD1 silenced cells (Fig. 2C), implying disabled mitochondrial
biogenesis when DHTKD1 insufﬁcient. These ﬁndings suggest that
DHTKD1 controls mtDNA copy number through its effect on mito-
chondrial biogenesis.
3.3. DHTKD1 suppression causes increased ROS level
It is now well established that OGDHC is a source of ROS in
mitochondria, in addition to that produced in the mitochondrialFig. 2. Impaired mitochondrial biogenesis in DHTKD1 silenced cells. (A) MitoTracker Re
Decreased mtDNA copy numbers in DHTKD1 silenced HepG2 and U87MG cells. mtDN
template isolated from the indicated cells. (C) Mitochondrial biogenesis associated gene
were detected by RT-qPCR. All quantitative data is presented in means ± S.D. of three in
Fig. 3. Increased ROS level in DHTKD1 deﬁcient cells. (A) Knock-down (left) and over
cytometry. DCF was used as a ﬂuorescent indicator of cellular ROS. (B) Decreased ROS de
quantitative data is presented in means ± S.D. of three independent experiments. ⁄P < 0.electron transport chain [16]. It was recently discovered that mito-
chondrial ROS directly stimulates pathological conditions as
diverse as malignancies, autoimmune diseases, and neurodegener-
ative diseases which all share the common phenotype of increased
mtROS production [17]. Studies of ROS in DHTKD1-insufﬁcent
HepG2 showed increased resting ROS compared to controls
(Fig. 3A), indicating reduced ability to handle ROS in DHTKD1-
insufﬁcent cancer cells. Overexpression of DHTKD1 also produced
more ROS (Fig. 3A), implying that change of DHTKD1 dosage could
alter cellular oxidative stress. Among the enzymes of TCA cycle,
OGDHC is especially vulnerable to ROS [18], suggesting more mito-
chondrial ROS signals playing a role in OGDHC inactivity conﬁrmed
as above. Owing to the high reactivity and toxicity of ROS,
mammalian cells have evolved a number of antioxidant enzyme
systems to scavenge mtROS as soon as they are generated [17].
Decreased expression of ROS detoxifying enzymes including super-
oxide dismutase (SOD1), catalase (CAT) and glutathione peroxidase
1 (GPX1) was observed in DHTKD1-silenced cells (Fig. 3B), which
aligned with increased ROS levels by FACS as mentioned in the
previous section. Together, these data point to a scenario where
the mitochondrial dysfunction induced by the partial silencing of
DHTKD1 caused the status of mitochondrial dysfunction with sus-
tained ROS imbalance is sufﬁcient to exacerbate mtDNA reduction
and aberrant mitochondrial gene expression.
3.4. Silencing of DHTKD1 induces cell apoptosis
To investigate whether insufﬁcient ATP and excessive ROS level
would inﬂuence cell growth, we detected cell viability using MTT
assay. The results showed that suppression of DHTKD1 in HepG2d staining showed decreased mitochondrial mass in DHTKD1 silenced HepG2. (B)
A (COX1 and CYTB)/nDNA (H19) ratio was determined by real-time qPCR on DNA
s were decreased in DHTKD1 silenced cells. mRNA expression level of these genes
dependent experiments. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
expression (right) of DHTKD1 increased cellular ROS level determined with ﬂow
fense genes expression in DHTKD1 deﬁcient cells determined through RT-qPCR. All
05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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much more slowly than controls (Fig. 4A). To examine whether
cells undergo apoptosis, DHTKD1 silenced cells were stained with
annexin V and propidium iodide (PI). As shown, lack of DHTKD1 re-
sulted in higher early apoptotic population compared to controls
(17.44 ± 0.1861% and 18.61 ± 0.2768% vs. 10.53 ± 1.574%) (Fig. 4B
and C). Next we examined the cell cycle distribution; we found that
inhibition of DHTKD1 would not impact cell cycles (Fig. 4D). Thus,
these results indicate that energy shortage in DHTKD1-insufﬁcient
human cancer cells inhibits cell proliferation and induces early
apoptosis, suggesting an essential role for DHTKD1 in normal cell
growth and development.
4. Discussion
Mitochondrial dysfunction is a fundamental problem associated
with many neurological diseases, such as Alzheimer’s disease,
Huntington’s disease, Parkinson’s disease, amyotrophic lateral
sclerosis and many peripheral entrapment neuropathies [19].
Central nervous system functions greatly depend on the efﬁcient
mitochondrial function because of a high requirement for energy
in brain tissue. mtDNA mutation, mitochondrial dynamic defect,
ROS production and other environmental factors could change
energy metabolism [20].
For a long time, we have always thought that the main function
of mitochondria is to produce energy via OXPHOS [19]. Now,Fig. 4. DHTKD1 deﬁciency leads to cell apoptosis. (A) Retarded cell proliferation in DHTK
based on MTT method. (B and C) Apoptosis assays of the indicated cells. siRNA transfect
four-quadrant diagrams (C) and quantitative data (B) of percentage of apoptotic cells
quantitative data is presented in means ± S.D. of three independent experiments. ⁄P < 0.people are more inclined to believe that the dynamic network of
mitochondria not only connects distal cellular compartments
physically, but also makes great contribution to cellular life and
death [21,22]. In addition to ATP generation, mitochondria also
participate in various crucial pathways, such as calcium ions bal-
ance [23], iron–sulfur clusters synthesis [24] and apoptosis regula-
tion [25]. To illuminate mechanisms of DHTKD1 in the impact of
energy production in mitochondria, we suppressed DHTKD1 by
using speciﬁc oligomers against different DHTKD1 mRNA regions.
Response to the suppression, ATP level in DHTKD1-insufﬁecient
HepG2 cells was signiﬁcantly less than that in controls. Corre-
sponding to this change, decreased expression levels of OXPHOS
genes have been found. To further understand the mechanism link-
ing mitochondrial function to ATP generation, we measured the
activity of OGDHC in the HepG2 cells. Consistent with the de-
creased ATP level, OGDHC, the rate-limiting multienzyme complex
showed modest downward trends. As a multienzyme complex in
TCA, the direct correlation of OGDHC activity and TCA dysfunction
is demonstrated. However, it remains unknown whether this
impairment of OGDHC activity is secondary to ATP failure or a con-
tributor to the progression of ATP decrease. We demonstrate that
decreased ATP production is presumed to be substantial evidence
pointing to a critical role of DHTKD1 in mitochondrial functions.
Mitochondria use OXPHOS to produce ATP, as well as ROS,
which can cause respiratory chain defect, DNA damage and cell cy-
cle checkpoint activation [26]. In this study, we ﬁnd that inhibitionD1 silenced cells. Proliferation curve of cells transfected with the indicated siRNAs
ed cells were stained with FITC-annexin V and PI for ﬂow cytometric analysis. The
were shown. (D) Cell cycle analysis of the indicated siRNAs transfected cells. All
05, ⁄⁄P < 0.01.
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marked depressed expression of a number of antioxidant genes,
which would further exacerbate the ROS damage. The reductions
in PGC-1b and its target genes NRF1 and TFAM, which control many
aspects of mitochondrial biogenesis, further conﬁrm that increased
ROS would substantially induce the mitochondrial defect and asso-
ciate with neurodegenerative diseases.
Mitochondrial dysfunction results in a decline mitochondrial
biogenesis which can cause mtDNA reduction and thus would
drive further decline in mitochondrial function [20]. Besides oxida-
tive damage, mtDNA depletion leading to mitochondrial dysfunc-
tion emerges as an important element of neurological disorders.
In the present study, a signiﬁcant different content of mtDNA in
DHTKD1-insufﬁcent HepG2 cells and controls was proved. We
demonstrate that the decrease in mtDNA amount may be a result
of the defect of mitochondrial biogenesis and function. Production
of substantial amounts of ROS reduces mtDNA. In turn, mtDNA
deﬁciency in DHTKD1-insufﬁcent cells in our study may have con-
tributed to this ROS accumulation.
Cellular abnormalities are associated with different types of
mitochondrial dysfunctions. Without normal function mainte-
nance of mitochondria, cell function, signaling pathways and over-
all cell activities were inﬂuenced, leading to cell apoptosis and
other dynamic movements defect. There is much evidence indicat-
ing that increased oxidative stress and abnormal apoptosis are
associated with the pathogenesis of several ageing-related neuro-
degenerative disorders [27]. Further work deﬁne the abnormal
mitochondrial function involved in the silencing of DHTKD1 cause
retarded cell proliferation and increased trend forward cell apopto-
sis. Our study conﬁrms the role of mitochondria in the pathogene-
sis of cell growth.
Given the central importance of DHTKD1in mitochondria, we
reveal the fact that any genetic mutation in DHTKD1 resulting in
signiﬁcantly decreased mitochondrial biogenesis or function could
cause mitochondrial dysfunction and oxidative stress, involved in
the onset and progression of neurological decline like CMT2Q.
From this perspective, it is worth noting that there are many
important roles of DHTKD1 in mitochondrial biogenesis and func-
tion. In summary, identiﬁcation of the molecular mechanisms of
this highly conserved gene underlying neurological diseases is of
great importance in evaluating its role in mitochondrial function.
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